Human CD27/TNFRSF7 Antibody
R&D Systems, part of Bio-Techne | Catalog # MAB382
Scientific images may be resized, cropped, or adjusted for brightness or contrast for presentation purposes. These updates are limited to presentation and do not affect the underlying scientific interpretation of the data. Where available, additional source data may be provided upon request.
Key Product Details
Species Reactivity
Validated:
Cited:
Applications
Validated:
Cited:
Label
Antibody Source
Product Specifications
Immunogen
Thr21-Ile192
Accession # P26842
Specificity
Clonality
Host
Isotype
Endotoxin Level
Scientific Data Images for Human CD27/TNFRSF7 Antibody
CD27/TNFRSF7 Inhibition of CD27 Ligand/TNFSF7-dependent Cell Proliferation and Neutralization by Human CD27/TNFRSF7 Antibody.
In the presence of sub-optimal amounts of Mouse CD3e Monoclonal Anti-body (Catalog # MAB484) and Recombinant Mouse CD27 Ligand (10 µg/mL, Catalog # 783-CL), Recombinant Human CD27 Fc Chimera (Catalog # 382-CD) inhibits proliferation in mouse splenic T cells in a dose-dependent manner (orange line). Under these conditions, inhibition of proliferation elicited by Recombinant Human CD27 Fc Chimera (3 µg/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Human CD27 Monoclonal Antibody (Catalog # MAB382). The ND50 is typically 0.2-0.4 µg/mL.Applications for Human CD27/TNFRSF7 Antibody
CyTOF-ready
Flow Cytometry
Sample: Human whole blood lymphocytes
Western Blot
Sample: Recombinant Human CD27/TNFRSF7 Fc Chimera (Catalog # 382-CD)
Neutralization
Formulation, Preparation, and Storage
Purification
Reconstitution
Formulation
Shipping
Stability & Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: CD27/TNFRSF7
Human CD27 is a lymphocyte-specific member of the TNF receptor superfamily. CD27 is expressed on a subset of human thymocytes and on the majority of mature T cells. CD27 expression is up-regulated after TCR stimulation. Within the CD4+ compartment, it is preferentially expressed on CD45RA+ cells. In contrast, it is preferentially expressed on CD45RO+ cells in the CD8+ compartment. CD27 also appears to be a potential marker for memory B cells. It exists as both a disulfide‑linked dimer on the cell surface and as a soluble protein found in serum. Human CD27 is a 260 amino acid (aa) protein with a 20 aa signal, a 173 aa extracellular domain, a 20 aa transmembrane domain, and a 47 aa cytoplasmic domain. The ligand for CD27 is CD70. CD70 is expressed on thymic stromal cells and a small subset of activated T cells. Additionally a subset of activated B cells express CD70. The CD27/CD70 interaction appears to be a weak costimulatory pathway involved in T cell and B cell immune response. CD27/CD70 interactions may be more involved in controlling the expansion phase of an immune response. This would be in contrast to B7/CD28 interactions, which are important for the activation phase of immune responses.
References
- Camerini, D. et al. (1991) J. Immunol. 147:3165.
- Loenen, W.A. et al. (1992) J. Immunol. 149:3937.
- Lens, S.M.A. et al. (1998) Sem. Immunol. 10:491.
Alternate Names
Gene Symbol
UniProt
Additional CD27/TNFRSF7 Products
Product Documents for Human CD27/TNFRSF7 Antibody
Product Specific Notices for Human CD27/TNFRSF7 Antibody
For research use only